Telix Pharmaceuticals (ASX:TLX) has announced that the last patient has been imaged in a phase one clinical study of the company's investigational prostate cancer imaging product TLX591-CDx. …
Telix Japanese prostate cancer imaging study completes enrolment
September 9, 2021 Australian Biotech
Latest Video
New Stories
-
Patient voices take centre stage at the 2026 Patient's Choice Awards
June 3, 2026 - - Latest News -
Officials confirm shift in Budget management of underspends
June 3, 2026 - - Latest News -
Invitation confusion clouds Delphi studies and captures medical device sector
June 3, 2026 - - Latest News -
Omico opens a new chapter in precision oncology research
June 1, 2026 - - Latest News -
Ex-MA executive named the first CEO of Medicinal Cannabis Council Australia
June 1, 2026 - - Latest News -
Oral RAS inhibitor doubles median survival and cuts death risk in metastatic pancreatic cancer
June 1, 2026 - - Latest News -
Australia risks losing more than jobs in its biopharmaceutical sector — it risks losing strategic capability
June 1, 2026 - - Latest News